Database : MEDLINE
Search on : neoplasms [Words]
References found : 1916494 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 191650 go to page                         

  1 / 1916494 MEDLINE  
              next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 25320534
[Au] Autor:Yan JF; Xu XW; Jin WW; Huang CJ; Chen K; Zhang RC; Harsha A; Mou YP
[Ad] Address:Jia-Fei Yan, Xiao-Wu Xu, Wei-Wei Jin, Chao-Jie Huang, Ke Chen, Ren-Chao Zhang, Ajoodhea Harsha, Yi-Ping Mou, Department of General Surgery, Sir Run Run Shaw Hospital, Institute of Micro-invasive Surgery, Zhejiang University School of Medicine, Hangzhou 310016, Zhejiang Province, China....
[Ti] Title:Laparoscopic spleen-preserving distal pancreatectomy for pancreatic neoplasms: A retrospective study.
[So] Source:World J Gastroenterol;20(38):13966-72, 2014 Oct 14.
[Is] ISSN:2219-2840
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:AIM: To describe the clinical characteristics, technical procedures, and outcomes of patients undergoing laparoscopic spleen-preserving distal pancreatectomy (LSPDP) for benign and malignant pancreatic neoplasms. METHODS: The clinical data of 38 patients who underwent LSPDP in the Sir Run Run Shaw Hospital between January 2003 and August 2013 were analyzed retrospectively. Surgical techniques for LSPDP included preservation of the splenic artery and vein (Kimura's technique) and ligation of the splenic pedicle with preservation of the short gastric vessels (Warshaw's technique). RESULTS: There were no conversions to open surgery in the 38 patients. Splenic vessels were conserved during spleen-preserving pancreatectomy, except in two patients who underwent resection of the splenic vessels and preservation only of the short gastric vessels. The mean operation time was 123.2 ± 52.4 min, the mean intraoperative blood loss was 78.2 ± 39.5 mL, and the mean postoperative hospital stay was 7.6 ± 2.9 d. The overall rate of postoperative complications was 18.4% (7/38), and the rate of clinical pancreatic fistula was 13.2% (5/38). All postoperative complications were treated conservatively. The postoperative pathological diagnoses were 22 cases of benign pancreatic disease and 16 cases of borderline or low-grade malignant lesions. During a median follow-up of 38 mo (range: 5-133 mo), no recurrence was observed. CONCLUSION: LSPDP is a safe, feasible and effective procedure for the treatment of benign and low-grade malignant tumors of the distal pancreas.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1410
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.3748/wjg.v20.i38.13966

  2 / 1916494 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 25320687
[Au] Autor:Mirza S; Fadl S; Napaki S; Abualruz A
[Ad] Address:Radiology Department, Hamad Medical Corporation, Doha, Qatar....
[Ti] Title:Case report of complicated epidermoid cyst of the floor of the mouth: Radiology-histopathology correlation.
[So] Source:Qatar Med J;2014(1):12-6, 2014.
[Is] ISSN:0253-8253
[Cp] Country of publication:Qatar
[La] Language:eng
[Ab] Abstract:Epidermoid cysts, true dermoid cysts and teratoid cysts compose the spectrum of cystic teratomas, which are defined as neoplasms whose tissue are derivatives of more than one germ layer, foreign to that part of the body from which the tumor arises. Epidermoid cysts of the floor of the mouth are rare lesions and are much less common than dermoid cysts in the head and neck. This case reports a 43-year-old male patient who presented with a longstanding midline swelling in the submental region. Initial imaging was done using ultrasound followed by computed tomography (CT) scan. Biopsy was taken and revealed a cyst wall lined with epidermal squamous epithelium along with areas of focal ulceration suggesting chronic inflammatory changes of the wall of the epidermoid cyst. There are characteristic and even pathognomonic imaging features of epidermoid cysts at the floor of the mouth in ultrasound and CT scan. Imaging has an important role in the surgical management plan according to the size and location of the cyst in relation to geniohyoid and mylohyoid muscles.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1410
[Cu] Class update date: 141018
[Lr] Last revision date:141018
[Da] Date of entry for processing:141016
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.5339/qmj.2014.2

  3 / 1916494 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 25317353
[Au] Autor:Bründl E; Schödel P; Ullrich OW; Brawanski A; Schebesch KM
[Ad] Address:Department of Neurosurgery, University Medical Center Regensburg, Germany....
[Ti] Title:Surgical resection of sporadic and hereditary hemangioblastoma: Our 10-year experience and a literature review.
[So] Source:Surg Neurol Int;5:138, 2014.
[Is] ISSN:2229-5097
[Cp] Country of publication:India
[La] Language:eng
[Ab] Abstract:BACKGROUND: Hemangioblastomas (HBLs) are benign neoplasms that contribute to 1-2.5% of intracranial tumors and 7-12% of posterior fossa lesions in adult patients. HBLs either evolve hereditarily in association with von Hippel-Lindau disease (vHL) or, more prevalently, as solitary sporadic tumors. Only few authors have reported on the clinical presentation and the neurological outcome of HBL. METHODS: We retrospectively analyzed the clinical, radiological, surgical, and histopathologic records of 24 consecutive patients (11 men, 13 women; mean age 51.3 years) with HBL of the posterior cranial fossa, who had been treated at our center between 2001 and 2012. We reviewed the current literature, and discussed our findings in the context of previous publications on HBL. The study protocol was approved by the local ethics committee (14-101-0070). RESULTS: Mean time to diagnosis was 14 weeks. The extent of resection (EOR) was total in 20 and near total in 4 patients. Four patients required revision within 24 h because of relevant postoperative bleeding. One patient died within 14 days. One patient required permanent shunting. At discharge, 75% of patients [n = 18, modified Rankin scale (mRS) 0-1] showed no or at least resolved symptoms. Mean follow-up was 21 months. Two recurrences were detected during follow-up. CONCLUSIONS: In comparison to other benign entities of the posterior fossa, time to diagnosis was significantly shorter for HBL. This finding indicates the rather aggressive biological behavior of these excessively vascularized tumors. In our series, however, the rate of complete resection was high, and morbidity and mortality rates were within the reported range.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1410
[Cu] Class update date: 141018
[Lr] Last revision date:141018
[Da] Date of entry for processing:141015
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.4103/2152-7806.141469

  4 / 1916494 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 25317275
[Au] Autor:Butler WE; Atai N; Carter B; Hochberg F
[Ad] Address:Neurosurgical Service, Massachusetts General Hospital, Boston, MA, USA ; Massachusetts General Hospital, Boston, MA, USA....
[Ti] Title:Informatic system for a global tissue-fluid biorepository with a graph theory-oriented graphical user interface.
[So] Source:J Extracell Vesicles;3, 2014.
[Is] ISSN:2001-3078
[Cp] Country of publication:Sweden
[La] Language:eng
[Ab] Abstract:The Richard Floor Biorepository supports collaborative studies of extracellular vesicles (EVs) found in human fluids and tissue specimens. The current emphasis is on biomarkers for central nervous system neoplasms but its structure may serve as a template for collaborative EV translational studies in other fields. The informatic system provides specimen inventory tracking with bar codes assigned to specimens and containers and projects, is hosted on globalized cloud computing resources, and embeds a suite of shared documents, calendars, and video-conferencing features. Clinical data are recorded in relation to molecular EV attributes and may be tagged with terms drawn from a network of externally maintained ontologies thus offering expansion of the system as the field matures. We fashioned the graphical user interface (GUI) around a web-based data visualization package. This system is now in an early stage of deployment, mainly focused on specimen tracking and clinical, laboratory, and imaging data capture in support of studies to optimize detection and analysis of brain tumour-specific mutations. It currently includes 4,392 specimens drawn from 611 subjects, the majority with brain tumours. As EV science evolves, we plan biorepository changes which may reflect multi-institutional collaborations, proteomic interfaces, additional biofluids, changes in operating procedures and kits for specimen handling, novel procedures for detection of tumour-specific EVs, and for RNA extraction and changes in the taxonomy of EVs. We have used an ontology-driven data model and web-based architecture with a graph theory-driven GUI to accommodate and stimulate the semantic web of EV science.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1410
[Cu] Class update date: 141018
[Lr] Last revision date:141018
[Da] Date of entry for processing:141015
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.3402/jev.v3.24247

  5 / 1916494 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 25312441
[Au] Autor:Nasser S; von Heymann C; Feldheiser A; Schäfer-Graf U; Klempert I; Pöllinger A; Krackhardt F; Henrich W; Sehouli J; Pietzner K
[Ad] Address:Department of Gynaecological Oncology Charite Comprehensive Cancer Centre, Charite - Universitaetsmedizin Berlin, Berlin, Germany saranasser27@gmail.com....
[Ti] Title:A rare case of ovarian cancer in pregnancy complicated by pulmonary embolus and myocardial infarction: management dilemmas.
[So] Source:J Surg Case Rep;2014(10), 2014.
[Is] ISSN:2042-8812
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Malignant ovarian neoplasms diagnosed during pregnancy at advanced stages are very rare. The clinical course and prognosis of pregnant patients diagnosed with epithelial ovarian cancer is similar to that of non-pregnant patients. We describe our management of a woman diagnosed with FIGO IIIc ovarian cancer at Caesarean section. Immediately after surgery she suffered a pulmonary embolus and a myocardial infarction. She showed signs of a severe pulmonary hypertension (59 mmHg). Four weeks later the pulmonary hypertension was still moderate but, despite her critical status, she underwent primary debulking surgery (PDS). This was performed under extensive anaesthesiological monitoring. Through this rare case, we show that despite the complex initial status of a critically ill patient, PDS can still remain the mainstay of treatment in patients with advanced ovarian cancer as most patients are able to tolerate even extensive debulking surgery without the need for neoadjuvant chemotherapy.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1410
[Cu] Class update date: 141018
[Lr] Last revision date:141018
[Da] Date of entry for processing:141014
[St] Status:PubMed-not-MEDLINE

  6 / 1916494 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
PubMed Central Full text
Full text

[PMID]: 25285790
[Au] Autor:Rosa RG; Goldani LZ
[Ad] Address:Infectious Diseases Unit, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
[Ti] Title:Factors Associated with Hospital Length of Stay among Cancer Patients with Febrile Neutropenia.
[So] Source:PLoS One;9(10):e108969, 2014.
[Is] ISSN:1932-6203
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:PURPOSE: This study sought to evaluate factors associated with hospital length of stay in cancer patients with febrile neutropenia. METHODS: A prospective cohort study was performed at a single tertiary referral hospital in southern Brazil from October 2009 to August 2011. All adult cancer patients with febrile neutropenia admitted to the hematology ward were evaluated. Stepwise random-effects negative binomial regression was performed to identify risk factors for prolonged length of hospital stay. RESULTS: In total, 307 cases of febrile neutropenia were evaluated. The overall median length of hospital stay was 16 days (interquartile range 18 days). According to multiple negative binomial regression analysis, hematologic neoplasms (P = 0.003), high-dose chemotherapy regimens (P<0.001), duration of neutropenia (P<0.001), and bloodstream infection involving Gram-negative multi-drug-resistant bacteria (P = 0.003) were positively associated with prolonged hospital length of stay in patients with febrile neutropenia. The condition index showed no evidence of multi-collinearity effect among the independent variables. CONCLUSIONS: Hematologic neoplasms, high-dose chemotherapy regimens, prolonged periods of neutropenia, and bloodstream infection with Gram-negative multi-drug-resistant bacteria are predictors of prolonged length hospital of stay among adult cancer patients with febrile neutropenia.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1410
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1371/journal.pone.0108969

  7 / 1916494 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25184630
[Au] Autor:Antonarakis ES; Lu C; Wang H; Luber B; Nakazawa M; Roeser JC; Chen Y; Mohammad TA; Chen Y; Fedor HL; Lotan TL; Zheng Q; De Marzo AM; Isaacs JT; Isaacs WB; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
[Ad] Address:From the Departments of Oncology (E.S.A., H.W., B.L., J.T.I., R.N., C.J.P., S.R.D., M.A.C., M.A.E.), Pathology (H.L.F., T.L.L., Q.Z., A.M.D.M.), and Urology (C.L., M.N., J.C.R., Yan Chen, W.B.I., J.L.), Johns Hopkins University School of Medicine, Baltimore; and Greehey Children's Cancer Research Institute (T.A.M., Yidong Chen) and the Department of Epidemiology and Biostatistics (Yidong Chen), University of Texas Health Science Center at San Antonio, San Antonio.
[Ti] Title:AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
[So] Source:N Engl J Med;371(11):1028-38, 2014 Sep 11.
[Is] ISSN:1533-4406
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor. We hypothesized that detection of androgen-receptor splice variant 7 messenger RNA (AR-V7) in circulating tumor cells from men with advanced prostate cancer would be associated with resistance to enzalutamide and abiraterone. METHODS: We used a quantitative reverse-transcriptase-polymerase-chain-reaction assay to evaluate AR-V7 in circulating tumor cells from prospectively enrolled patients with metastatic castration-resistant prostate cancer who were initiating treatment with either enzalutamide or abiraterone. We examined associations between AR-V7 status (positive vs. negative) and prostate-specific antigen (PSA) response rates (the primary end point), freedom from PSA progression (PSA progression-free survival), clinical or radiographic progression-free survival, and overall survival. RESULTS: A total of 31 enzalutamide-treated patients and 31 abiraterone-treated patients were enrolled, of whom 39% and 19%, respectively, had detectable AR-V7 in circulating tumor cells. Among men receiving enzalutamide, AR-V7-positive patients had lower PSA response rates than AR-V7-negative patients (0% vs. 53%, P=0.004) and shorter PSA progression-free survival (median, 1.4 months vs. 6.0 months; P<0.001), clinical or radiographic progression-free survival (median, 2.1 months vs. 6.1 months; P<0.001), and overall survival (median, 5.5 months vs. not reached; P=0.002). Similarly, among men receiving abiraterone, AR-V7-positive patients had lower PSA response rates than AR-V7-negative patients (0% vs. 68%, P=0.004) and shorter PSA progression-free survival (median, 1.3 months vs. not reached; P<0.001), clinical or radiographic progression-free survival (median, 2.3 months vs. not reached; P<0.001), and overall survival (median, 10.6 months vs. not reached, P=0.006). The association between AR-V7 detection and therapeutic resistance was maintained after adjustment for expression of full-length androgen receptor messenger RNA. CONCLUSIONS: Detection of AR-V7 in circulating tumor cells from patients with castration-resistant prostate cancer may be associated with resistance to enzalutamide and abiraterone. These findings require large-scale prospective validation. (Funded by the Prostate Cancer Foundation and others.).
[Mh] MeSH terms primary: Androstenols/therapeutic use
Drug Resistance, Neoplasm/genetics
Phenylthiohydantoin/analogs & derivatives
Prostatic Neoplasms/genetics
RNA, Neoplasm/analysis
Receptors, Androgen/genetics
[Mh] MeSH terms secundary: Humans
Male
Morphinans/analysis
Phenylthiohydantoin/therapeutic use
Prostatic Neoplasms/drug therapy
Receptors, Androgen/analysis
Reverse Transcriptase Polymerase Chain Reaction
Survival Analysis
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Name of substance:0 (Androstenols); 0 (MDV 3100); 0 (Morphinans); 0 (RNA, Neoplasm); 0 (Receptors, Androgen); 154229-19-3 (abiraterone); 2010-15-3 (Phenylthiohydantoin); 61799-82-4 (Mr 1257 MS)
[Em] Entry month:1409
[Cu] Class update date: 141018
[Lr] Last revision date:141018
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:140911
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMoa1315815

  8 / 1916494 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 24916333
[Au] Autor:Jung AY; van Duijnhoven FJ; Nagengast FM; Botma A; Heine-Bröring RC; Kleibeuker JH; Vasen HF; Harryvan JL; Winkels RM; Kampman E
[Ad] Address:Department for Health Evidence, Radboud University Medical Center, Nijmegen, Netherlands.
[Ti] Title:Dietary B vitamin and methionine intake and MTHFR C677T genotype on risk of colorectal tumors in Lynch syndrome: the GEOLynch cohort study.
[So] Source:Cancer Causes Control;25(9):1119-29, 2014 Sep.
[Is] ISSN:1573-7225
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:PURPOSE: Dietary intake of B vitamins and methionine, essential components of DNA synthesis and methylation pathways, may influence colorectal tumor (CRT) development. The impact of B vitamins on colorectal carcinogenesis in individuals with Lynch syndrome (LS) is unknown but is important given their high lifetime risk of developing neoplasms. The role of MTHFR C677T genotype in modifying these relationships in LS individuals is also unclear. We investigated associations between dietary intakes of folate, vitamins B2, B6, B12, and methionine and CRT development in a prospective cohort study of 470 mismatch repair gene mutation carriers. METHODS: Dietary intakes were assessed by food frequency questionnaire. Cox regression models with robust sandwich covariance estimation, adjusted for age, sex, physical activity, number of colonoscopies during person-time, NSAID use, and mutual vitamins were used to calculate hazard ratios (HRs) and 95 % confidence intervals (95 % CIs). Analyses were also stratified by MTHFR C677T genotype. RESULTS: During a median person-time of 28.0 months, 131 persons developed a CRT. Fifty-one of these persons developed an incident colorectal adenoma, while there were four persons who developed an incident colorectal carcinoma. Compared to the lowest tertile of intake, adjusted HRs (95 % CIs) for CRT development in the highest tertile were 1.06 (0.59-1.91) for folate, 0.77 (0.39-1.51) for vitamin B2, 0.98 (0.59-1.62) for vitamin B6, 1.24 (0.77-2.00) for vitamin B12, and 1.36 (0.83-2.20) for methionine. Low vitamin B2 and low methionine intake were statistically significantly associated with an increased risk of CRT in MTHFR 677TT individuals compared to a combined reference of persons with low intake and CC genotype. CONCLUSIONS: There was no suggestion that intake of any dietary B vitamin or methionine was associated with CRT development among those with LS.
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Entry month:1409
[Js] Journal subset:IM
[St] Status:In-Process
[do] DOI:10.1007/s10552-014-0412-4

  9 / 1916494 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25128497
[Au] Autor:Huang CH; Lujambio A; Zuber J; Tschaharganeh DF; Doran MG; Evans MJ; Kitzing T; Zhu N; de Stanchina E; Sawyers CL; Armstrong SA; Lewis JS; Sherr CJ; Lowe SW
[Ad] Address:Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA; Cell and Developmental Biology Program, Weill Graduate School of Medical Sciences, Cornell University, New York, New York 10065, USA; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA;...
[Ti] Title:CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma.
[So] Source:Genes Dev;28(16):1800-14, 2014 Aug 15.
[Is] ISSN:1549-5477
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:One-year survival rates for newly diagnosed hepatocellular carcinoma (HCC) are <50%, and unresectable HCC carries a dismal prognosis owing to its aggressiveness and the undruggable nature of its main genetic drivers. By screening a custom library of shRNAs directed toward known drug targets in a genetically defined Myc-driven HCC model, we identified cyclin-dependent kinase 9 (Cdk9) as required for disease maintenance. Pharmacological or shRNA-mediated CDK9 inhibition led to robust anti-tumor effects that correlated with MYC expression levels and depended on the role that both CDK9 and MYC exert in transcription elongation. Our results establish CDK9 inhibition as a therapeutic strategy for MYC-overexpressing liver tumors and highlight the relevance of transcription elongation in the addiction of cancer cells to MYC.
[Mh] MeSH terms primary: Carcinoma, Hepatocellular/enzymology
Cyclin-Dependent Kinase 9/metabolism
Liver Neoplasms/enzymology
Proto-Oncogene Proteins c-myc/metabolism
Transcription Elongation, Genetic/physiology
[Mh] MeSH terms secundary: Animals
Carcinoma, Hepatocellular/genetics
Carcinoma, Hepatocellular/pathology
Cell Line, Tumor
Cell Proliferation
Female
Gene Expression
Gene Library
Hep G2 Cells
Humans
Liver Neoplasms/genetics
Liver Neoplasms/pathology
Mice
Positive Transcriptional Elongation Factor B/genetics
Positive Transcriptional Elongation Factor B/metabolism
Proto-Oncogene Proteins c-myc/genetics
RNA Interference
RNA, Small Interfering/metabolism
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Myc protein, mouse); 0 (Proto-Oncogene Proteins c-myc); 0 (RNA, Small Interfering); EC 2.7.11.- (Positive Transcriptional Elongation Factor B); EC 2.7.11.22 (Cyclin-Dependent Kinase 9)
[Em] Entry month:1410
[Cu] Class update date: 141018
[Lr] Last revision date:141018
[Js] Journal subset:IM
[Da] Date of entry for processing:140816
[St] Status:MEDLINE
[do] DOI:10.1101/gad.244368.114

  10 / 1916494 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 24923630
[Au] Autor:Hosseini A; Baker JL; Tokin CA; Qin Z; Hall DJ; Stupak DG; Hayashi T; Wallace AM; Vera DR
[Ad] Address:Department of Surgery, University of San Diego, California....
[Ti] Title:Fluorescent-tilmanocept for tumor margin analysis in the mouse model.
[So] Source:J Surg Res;190(2):528-34, 2014 Aug.
[Is] ISSN:1095-8673
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Dendritic cells (DC) are localized in close proximity to cancer cells in many well-known tumors, and thus maybe a useful target for tumor margin assessment. MATERIALS AND METHODS: [(99m)Tc]- cyanine 7 (Cy7)-tilmanocept was synthesized and in vitro binding assays to bone marrow-derived DC were performed. Fifteen mice, implanted with either 4T1 mouse mammary or K1735 mouse melanoma tumors, were administered 1.0 nmol of [(99m)Tc]-Cy7-tilmanocept via tail vein injection. After fluorescence imaging 1 or 2 h after injection, the tumor, muscle, and blood were assayed for radioactivity to calculate percent-injected dose. Digital images of the tumors after immunohistochemical staining for DC were analyzed to determine DC density. RESULTS: In vitro binding demonstrated subnanomolar affinity of [(99m)Tc]-Cy7-tilmanocept to DC (KA = 0.31 ± 0.11 nM). After administration of [(99m)Tc]-Cy7-tilmanocept, fluorescence imaging showed a 5.5-fold increase in tumor signal as compared with preinjection images and a 3.3-fold difference in fluorescence activity when comparing the tumor with the surgical bed after tumor excision. Immunohistochemical staining analysis demonstrated that DC density positively correlated with tumor percent of injected dose per gram (r = 0.672, P = 0.03), and higher DC density was observed at the periphery versus center of the tumor (186 ± 54 K versus 64 ± 16 K arbitrary units, P = 0.001). CONCLUSIONS: [(99m)Tc]-Cy7-tilmanocept exhibits in vitro and in vivo tumor-specific binding to DC and maybe useful as a tumor margin targeting agent.
[Mh] MeSH terms primary: Benzothiazoles/diagnostic use
Carbocyanines/diagnostic use
Dendritic Cells/pathology
Dextrans/diagnostic use
Mammary Neoplasms, Experimental/pathology
Mannans/diagnostic use
Melanoma, Experimental/pathology
Technetium Tc 99m Pentetate/analogs & derivatives
[Mh] MeSH terms secundary: Animals
Antigens, CD11c/analysis
Antigens, CD11c/chemistry
Benzothiazoles/chemistry
Carbocyanines/chemistry
Cell Line
Cell Line, Tumor
Dendritic Cells/chemistry
Dextrans/chemistry
Female
Mammary Neoplasms, Experimental/chemistry
Mannans/chemistry
Melanoma, Experimental/chemistry
Mice
Mice, Inbred BALB C
Mice, Inbred C3H
Microscopy, Fluorescence
Technetium Tc 99m Pentetate/chemistry
Technetium Tc 99m Pentetate/diagnostic use
Ultraviolet Rays/diagnostic use
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Antigens, CD11c); 0 (Benzothiazoles); 0 (Carbocyanines); 0 (Mannans); 0 (technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran); 57282-58-3 (cyanine dye 7); K3R6ZDH4DU (Dextrans); VW78417PU1 (Technetium Tc 99m Pentetate)
[Em] Entry month:1409
[Cu] Class update date: 141018
[Lr] Last revision date:141018
[Js] Journal subset:IM
[Da] Date of entry for processing:140712
[St] Status:MEDLINE


page 1 of 191650 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information